Hyaluronidase Injection

This page does not provide a fixed online price quote. The final fee depends on physician assessment, treatment area, product amount or brand, combination planning and medical suitability.

Description

Hyaluronidase injection is a procedure of injecting the enzyme that depolymerizes the hyaluronic acid polymer in a controlled manner in order to reverse the undesirable results of HA (hyaluronic acid) fillers. The procedure breaks down the HA filler into disaccharide and monomer particles using hyaluronidase (Hylenex, Hyalase, AKE-GR) of animal origin or prepared in recombinant enzyme form. Particles enter the lymphatic and blood circulation, providing systemic clearance. The procedure can be performed as non-surgical, minimally invasive, anesthesia-free or with local anesthesia, and the protocol is customized according to the severity of the complication and its indication — it is the HA filler reversal method that covers a wide spectrum, from mild clinical findings such as the Tyndall effect to life-threatening emergencies such as vascular occlusion.

Brief Summary About Enzyme

Hyaluronidase Definition: Hyaluronidase (hyaluronic acid-specific hydrolase; EC 3.2.1.35) is an enzyme that is naturally found in the body and has the capacity to hydrolyze and cut the β-1,4 and β-1,3 glycosidic bonds of the hyaluronic acid (HA) polymer chain. For more detailed information, see Hyaluronidase (Drug) — Enzyme Page. This page describes the injection procedure, techniques, dosing algorithms, and clinical applications of hyaluronidase.

Indications

1. Tyndall Effect

Bluish-purplish optical appearance under the skin after HA filler is injected into the superficial dermis (<2 mm). Short wavelengths of light (blue) are scattered in the HA colloid (Tyndall physical scattering), while long wavelengths (red) are absorbed. Due to the difference in hypodermal HA transparency and particle size, skin thickness and refractive index. Risk areas: tear trough, lip vermillion edge, lateral canthal lines. Hyaluronidase usually dissolves in 24-72 hours with 5-10 U local injection "pulse" technique.

2. Nodule / Granuloma (Filler Nodule)

Palpable, firm, sometimes painful or hyperemic nodule from aseptic granulomatous reaction or biofilm formation. Etiology: over-concentration HA, foreign body immune response (Type IV delayed hypersensitivity), contamination, repeated injections. Hyaluronidase accelerates macrophage clearance by rupturing the nodule with local injection of 15-30 U; combined oral antibiotic (clarithromycin) and intralesional injection of triamcinolone 10-20 mg/mL. Resolution is usually observed after 1-2 weeks.

3. Overfilling / Over-Correction

Hard, artificial appearance, grotesque swelling, asymmetry after excessive HA injection into the target area. Patients' dissatisfaction is high. Hyaluronidase partial reversal — excess volume is reduced while the natural contour is preserved. 30-150 U is distributed into the problematic area and re-evaluated after 1-2 weeks.

4. Filler Migration

Displacement of the HA filler over time (weeks to months) from the original location where it was injected. Mechanical (gravity, mimic pressure), biological (HA hydrophilicity, toughness compliance difference). For example: lip filler vermillion up ("duck lips"), lateral malar thickening. Hyaluronidase, 15-30 U targeted injection (to the migraine area), provides complete resorption after 2-4 weeks. Massage is strictly prohibited (paradoxically, it increases migration).

5. Filler-Related Asymmetry

In bilateral areas (lips, cheeks, chin) after injection, one side is overfilled, the other is normal or slightly. Hyaluronidase partial reversal provides hemography rescue with injection of 10-20 U on the extreme side. Re-evaluate after 1-2 weeks.

6. Ptosis (Filler-Induced Compression Ptosis)

Ptosis (eyelid drooping) after HA injection (especially superficial or around the eyes when volume is excessive) compresses the levator palpebrae superior muscle. Compression is relieved by injection of hyaluronidase 5-8 U in the periorbital area (avoiding the danger zone of the medial canthus and supratrochlear artery). The result is seen in 48-72 hours.

7. Vascular Occlusion — EMERGENCY INDICATION

Embolization + distal ischemia + necrosis + potential blindness as a result of inadvertent injection of HA filler into the arterial lumen (ophthalmic artery retrograde embolization). The most serious complication of fillers. Clinical findings: blanching (pallor), severe pinpoint pain (disproportionate), livedo reticularis, black/purple pole, headache, visual impairment (MINUTES critical). Hyaluronidase 450-1500 U high-dose flood technique initiates reperfusion by completely saturating the embolized vascular zone. Very urgent: nitroglycerin topical, aspirin, pentoxifylline IV, hyperbaric oxygen (at current center), OPHTHALMOLOGY URGENT (retrobulbar hyaluronidase is controversial in suspected visual impairment).

Contraindications

Absolute Contraindications

• Hyaluronidase Allergy/Anaphylaxis History: If you have previously had a severe reaction to hyaluronidase (anaphylaxis, serum sickness, angioedema), the procedure is strictly avoided or trialled on a light dose. In emergency scenarios (vascular occlusion) allergy is managed with dialysis/epinephrine ready.
• Honey Bee/Wasp Venom Allergy (Bovine Products): Cross-reactivity risk 0.05-0.1%; If you have had a severe allergy to hyaluronidase of animal origin, prefer recombinant or skin test therapeutic use.
• Pregnancy: FDA Category C (limited data). Serious filler complications requiring treatment are rare during pregnancy — delay, seek obstetric consultation.
• Breastfeeding (Relative): Low risk since systemic absorption is minimal; However, precaution is recommended.

Relative Contraindications (Pre-Treatment / Optimization)

• Active Skin Infection/Herpes: If herpes, acne, skin infection is active at the injection site, postpone the injection (risk of spreading infection).
• Autoimmune Disease (Systemic Lupus, Scleroderma, Sjögren's): Hyaluronidase may increase foreign protein response; Precaution, skin testing is recommended.
• Anticoagulant Therapy (Warfarin, DOAC): Risk of bleeding; INR control, coordination with the physician, special attention to injection technique (aspiration, bleeding control).

Pre-Procedure Testing and Preparation

Allergic History Screening

Patient inquiry: honeybee allergy, atopy (eczema, vine, allergic rhinitis), previous drug reactions, autoimmune disease. When choosing a bovine product (AKE-GR), intradermal testing is recommended for patients in the atopy+allergic risk group. Testing is not required for recombinant selection.

Intradermal Patch Test (Optional, Bovine Products)

Protocol: Inject 0.02 mL hyaluronidase (150 U/mL saline dilution = 3 U test dose) into the volar forearm dermis. 15 minutes observation. Papule >3-4 mm diameter whealing + erythema halo = POSITIVE (allergy — avoid product, try recombinant or postpone procedure). Negative = proceed. Most clinics do not do testing in Turkey (time/cost) — the patient is given informed consent "risk of anaphylaxis 0.1-1%, skin test available".

Photo Documentation

Pre-procedure standardized photography (frontal, oblique, profile, detail shots) documents the location, severity and appearance of the complication — critical for post-operative comparison. Especially in acute cases of vascular occlusion, baseline visual documentation may gain legal/academic importance over time.

Informed Consent

The procedure is clearly explained to the patient: the mechanism of action of hyaluronidase, the expected timing of results (24-72 hours vs. weeks), side effects (local edema, erythema), risk of allergic reactions (0.1-1% for bovine products), minimal (selective) risk of non-HA tissue disruption, repeat injection may be required. Called urgent (vascular occlusion) — risk/benefit explained and ancillary procedures (NTG, aspirin, HBO) mentioned.

Dosage and Technique — Detailed Algorithm

Dosage Algorithm (According to Indication)

Tyndall Effect

• Dose: 5-10 U locally
• Technique: Pulse injection — small volume (0.05-0.1 mL), 2-3 points, direct to Tyndall area, 0.5-1.5 U every 0.1 mL
• Depth: 1-2 mm subdermalDepth to provide diffusion under HA injection
• Result timing: Mostly resolved within 24-72 hours

Nodule / Granuloma

• Dose: 15-30 U locally (or more in larger nodules)
• Technique: Direct injection into the nodule (disperse 5-10 U × 2-3 points around the nodule, or 15 U bolus into the nodule) + local massage 30 seconds
• Combination: Oral antibiotic (clarithromycin 500 mg × 2/day × 2-4 weeks) + intralesional triamcinolone 10-20 mg/mL (0.5 mL) after 1 week
• Results timing: 1-2 weeks (complete resolution of granuloma in 4+ weeks)

Overfilling / Over-Correction

• Dose: 30-150 U, depending on the severity of the problem (30 U minor overcorrection, 150 U massive overfill)
• Technique: Distributed injection into the problematic area (5-10 U dots, 10-20 dots/1 syringe filler in the area), local massage gently for 10-20 minutes to ensure ER penetration
• Timing of results: 1-2 weeks (partial reversal effect) — repeat injection may be necessary

Fill Migration

• Dose: 15-30 U targeted (according to migraine area localization)
• Technique: Direct injection into migraine area (multipoint 5-10 U distribution), NEVER massage (increases migration paradoxically)
• Result timing: 2-4 weeks complete resorption

Asymmetry (Filler-Related)

• Dose: 10-20 U on the extreme side
• Technique: Direct injection into the area of excessive volume (10-15 U bolus or 5 U multipoint), re-evaluate after 1-2 weeks

Vascular Occlusion — EMERGENCY PROTOCOL

• Dose: 450-1500 U (DeLorenzi flood technique)
• Technique: High-dose bolus injection — to completely saturate the embolized vascular zone, sparse distribution in 5-20 points, multi-syringe preparation (450 U first, additional if necessary)
• Timing: 0-5 minutes stop injection + hot application + massage; Start hyaluronidase injection for 5-10 minutes; 10-30 minutes nitroglycerin + aspirin + pentoxifylline IV + oxygen
• Ophthalmic artery suspicion: Retrobulbar hyaluronidase controversial (efficacy still uncertain) — STAT ophthalmology consultation, angiography, HBO (available)

Product Type and Preparation

Hylenex Recombinant (Halozyme)

• Concentration: 6.200 U lyophilized vial
• Preparation: Reconstituted with 1 mL of 0.9% saline = 6,200 U/mL stock solution
• Dilution (practical): 1 mL stock + 40 mL saline mix for 150 U/mL (sering 3 mL = 450 U); or for 300 U/mL, 1 mL stock + 20 mL saline (sering 1 mL = 300 U)
• Stability: Should be used within 4 hours after reconstitution (ambient); Stored in the refrigerator for up to 24 hours
• This page does not provide a fixed online price quote. The final fee depends on physician assessment, treatment area, product amount or brand, combination planning and medical suitability.
• Advantage: <0.01% anaphylaxis, no skin testing required

AKE-GR Bovine (Eczacıbaşı)

• Concentration: 1,500 U / 5 mL vial (300 U/mL); or 150 U micro-vial
• Preparation: Direct use or dilution (300 U/mL stock — no further dilutions may be required)
• Stability: Must be used within 6 hours after opening
• This page does not provide a fixed online price quote. The final fee depends on physician assessment, treatment area, product amount or brand, combination planning and medical suitability.
• Disadvantage: 0.1-1% risk of anaphylaxis; intradermal testing is recommended

Needle vs. Cannula Preference

• 30-32G fine needle: Peroral, Tyndall (delicate), nodule (direct intralesional) — rapid, precise, but slightly higher risk of vascular trauma
• 25-27G microcannula: Deep bolus (supraperiosteal), overfill (distributed), migration — retroactive aspiration possible, lower risk of vascular trauma, but depth control requires technical curve

Procedure Protocol (Step by Step)

Step 1: Pre-Anesthesia

Choice of local anesthesia: topical (EMLA cream, lidocaine gel, wait 30 minutes), block (infraorbital, mental, superior labial — for perioral), or intradermal lidocaine mini-injection (peroral sensitive areas). In case of vascular occlusion emergency, anesthesia is postponed (time is critical, technical control is important), topical benzocaine spray is used only for pain relief.

Step 2: Calming + Repeat Consent

The patient is reassured, the timing of the procedure, expected discomfort (injection pain is mild, minimal), timing of results, complications (allergic reaction is rare, but be prepared) is explained. Epinephrine, antihistamine and steroids are kept ready.

Step 3: Definition of HA Injection Location

The exact localization, depth and severity of the HA filler are determined by palpation, transillumination (endoscope/flashlight), ultrasound (in some clinics) and clinical evaluation. Tyndall: superficial blue halo; Nodule: hard bump; Overfill: hard, unsymmetrical bulge; Vascular occlusion: pale/livedo area.

Step 4: Hyaluronidase Preparation

The selected product (Hylenex recombinant or AKE-GR) is prepared, its dosage is calculated, syringe and needle/cannula are selected. Epinephrine, antihistamine, nitroglycerin, aspirin, pentoxifylline, oxygen standard close access control. Emergency case some prep.

Step 5: Hyaluronidase Injection

Tyndall effect: 5-10 U pulse technique, 2-3 points 0.5-1 cm apart, direct injection into the bluish area, local massage 30 seconds.

Nodule: 15-30 U, bolus into the nodule or 5 U multipoint (nodule + surrounding area), massage 30 seconds, start antibiotics (clarithromycin 500 mg × 2/day × 2-4 weeks orally)

Overfill: 30-150 U distributed into the problematic area, 5-10 U × 10-20 points distributed, local massage 20 minutes (penetration), observation for 1-2 weeks.

Vascular occlusion (URGENT): 450-1500 U flood technique, sparse injection at 5-20 points, saturate embolized zone, start systemic treatment immediately (BELOW).

Step 6: Local Massage

By indication: Tyndall (mild for 30 seconds), nodule (30 seconds), overfill (20 minutes), migration (DO NOT). Massage provides hyaluronidase diffusion and tissue penetration.

Step 7: Post-Procedure Observations

The patient's vitals are checked (BP, HR, O2 sat), signs of allergic reactions continue to be observed (fluid, itching, bronchospasm, andoedema - if anaphylaxis is suspected, IM epinephrine 0.3-0.5 mg). Total observation for 30-60 minutes. Cold compress can be applied for 15-20 minutes (optional, to relieve swelling).

Equipment and Product Types

Hyaluronidase Products

Product	Source	concentration	Risk of Anaphylaxis	Skin Test	Cost TR	preference
Hylenex Recombinant	Recombinant human (E. coli)	6.200 U lyophilized	<0.01%	no	This page does not provide a fixed online price quote. The final fee depends on physician assessment, treatment area, product amount or brand, combination planning and medical suitability.	Allergic group, emergency safety-first
AKE-GR	Bovine (Cow testicle)	1,500 U / 5 mL (300 U/mL)	0.1-1%	Recommended	This page does not provide a fixed online price quote. The final fee depends on physician assessment, treatment area, product amount or brand, combination planning and medical suitability.	Common in Türkiye, affordable price
Hyalase	Bovine (Cow testicle)	1,500 U / 5 mL	0.1-1%	Recommended	This page does not provide a fixed online price quote. The final fee depends on physician assessment, treatment area, product amount or brand, combination planning and medical suitability.	limited availability
Wydase	Bovine (Cow testicle)	1,500 U / 5 mL	0.1-1%	Recommended	This page does not provide a fixed online price quote. The final fee depends on physician assessment, treatment area, product amount or brand, combination planning and medical suitability.	import, rare

Injection Equipment

• 30-32G fine needle: Perioral, periorbit, nodule — precision and rapid injection
• 25-27G microcannula: Deep bolus, overfill — minimal risk of vascular trauma, retroactive aspiration
• 1 mL luer-lock syringe: Micro-dose control
• 3 mL syringe: Large volume distribution (overfill, vascular occlusion)
• Topical anesthetic: EMLA cream, lidocaine gel, benzocaine spray
• Emergency cart: Epinephrine IM 1:1000 (0.3-0.5 mg), antihistamine (diphenhydramine 50 mg IM/IV), steroid (methylprednisolone 125 mg IV), oxygen, saline, intubation kit (standby)

Side Effects and Complications

Expected Side Effects (Common, Temporary)

• Local edema: 24-48 hours, normal inflammation response; Solve it with cold compress, elevation
• Erythema (redness): 24-72 hours, injection trauma; Recommendation for topical steroid cream (desoximedthasone) and sun protection (SPF 30+)
• Mild pain/discomfort: 2-4 hours during and after injection; paracetamol 500-1000 mg PRN
• Ecchymosis (bruising/hematoma): After vascular trauma, arnica topical/oral 3-5 days, vitamin K cream (Auriderm)

Rare Side Effects

• Urticaria (hives) / Itching: Mild Type I hypersensitivity, antihistamine (cetirizine 10 mg) orally, locally topical antihistamine lotion (Caladryl)
• Local allergic reaction (dermatitis): Contact dermatitis at the injection site, steroid cream recommended 5-7 days
• Infection (Cellulitis): Post-injection bacterial contamination (S. epidermidis, P. acnes), temperature, discharge, haze — oral antibiotic (amoxicillin-clavulanic acid 500 mg × 3/day × 7-10 days) or IV cephalosporin in severe cases

Serious Side Effects (Very Rare)

• Anaphylactic Reaction (Anaphylaxis): 0.01-1% in bovine products, <0.01% in recombinant. Symptoms: tachycardia, bronchospasm, stridor, angioedema (lips, tongue, larynx), hypotension, syncope, fatal tracheitis. Treatment: URGENT — IM epinephrine 1:1000 (0.3-0.5 mg IM), immediately start IV saline, antihistamine (diphenhydramine 50 mg IV), steroid (methylprednisolone 125 mg IV), oxygen >10 L/min. STAT hospital reference and anesthesia standby.
• Serum Sickness-like Reaction: Hypersensitivity delayed reaction, starts in 48-72 hours, arthralgia (joint pain), myalgia (muscle pain), malaise, rash, fever. Treatment: NSAID (ibuprofen 400 mg × 3/day × 5-7 days) + steroid topical/oral (prednisolone 20 mg × 1/day × 3 days); Hospitalization is rare but serious.
• Non-HA Tissue Dissolution (Over-Dissolution): Too high dose of hyaluronidase or incorrect injection — may overdegrade native HA (skin, tendon, ligament, subcutaneous tissue HA) (theoretical risk because hyaluronidase is selective). Practical: very rare; Natural HA returns to normal dialysis (the body continues to produce) in 3-7 days. Experienced physicians keep the risk minimal with dose-controlled injection.

Result Timing

Tyndall Effect

• First effect: Starts in 6-12 hours (hyaluronidase enzyme is activated and provides diffusion)
• Visible improvement: in 24-48 hours (bluish image <50% reduction)
• Complete resolution: in 72 hours (mostly 90%+ dissolution)
• Minimal remaining: resolves completely after 1-2 weeks (re-injection if very light residue)

Nodule / Granuloma

• First week: Slight shrinkage (hyaluronidase + oral antibiotic + massage combination)
• 1-2 weeks: 50-70% shrinkage
• 2-4 weeks: Complete resolution (granuloma body absorption is completed)
• Note: Nodules with biofilm infection may require 4-6 weeks + repeated antibiotics or surgical drainage

Overfilling

• First 48 hours: 20-30% volume reduction
• 1 week: 50% reduction
• 2-4 weeks: 80%+ reduction (Slower if HA deep bolus)
• Note: When partial reversal is intended, re-evaluate after 2 weeks; Additional injection can be done if necessary

Fill Migration

• 1 week: Light repositioning (migrated tissue hyaluronidase diffusion begins to occur)
• 2-4 weeks: Complete resorption (HA natural clearing is provided, the singular is naturally restored)

Vascular Occlusion

• 0-30 minutes: Critical window — hyaluronidase injection and systemic therapy should be initiated, reperfusion scale (blanching → pink → normal) observed
• 1-2 hours: Early response — color improvement, pain relief observed (sign of success)
• 24 hours: If reperfusion is achieved, skin color is restored (minimal residual livedo)
• 48-72 hours: Full coloration and skin integrity restored
• Visual impairment: STAT ophthalmic therapy required at 0-2 hours — visual prognosis limited to retro-bulbar hyaluronidase or HBO (research stage)

Cost and Packaging

Product Cost (Türkiye, 2026)

• This page does not provide a fixed online price quote. The final fee depends on physician assessment, treatment area, product amount or brand, combination planning and medical suitability.
• This page does not provide a fixed online price quote. The final fee depends on physician assessment, treatment area, product amount or brand, combination planning and medical suitability.
• This page does not provide a fixed online price quote. The final fee depends on physician assessment, treatment area, product amount or brand, combination planning and medical suitability.

Procedure Package (Collected from Patient)

• This page does not provide a fixed online price quote. The final fee depends on physician assessment, treatment area, product amount or brand, combination planning and medical suitability.
• This page does not provide a fixed online price quote. The final fee depends on physician assessment, treatment area, product amount or brand, combination planning and medical suitability.
• This page does not provide a fixed online price quote. The final fee depends on physician assessment, treatment area, product amount or brand, combination planning and medical suitability.

Dr. Hamza Gemici Comment

"Hyaluronidase injection is the procedure that should be at the center of the most serious and important emergency tool set of every physician performing aesthetic applications. In my 25 years of practice, I have seen how important it is to reverse the complications of HA fillers in a timely, safe and effective way, to patient satisfaction and practice credibility. Hyaluronidase is a selective HA enzyme — natural tissue HA is renewed by the body in a short time, the filler dissolves permanently. Vascular occlusion in the emergency flood technique can be life-saving. Tyndall, Complete resolution is common after 1-2 weeks in healing complications such as nodule and overfill. It is critical to have hyaluronidase (Hylenex recombinant preferred, but AKE-GR is the economical option), epinephrine, antihistamine, nitroglycerin topical, aspirin, pentoxifylline IV, oxygen ready in every consultation room. Bee allergy) recombinant product and intradermal test, skin test is recommended in bovine selection. Diagnosis of vascular occlusion should be made within the 0-30 minute window. When symptoms of glabellar pallor, livedo reticularis, pinpoint pain, headache, visual impairment appear, a delay of seconds or even minutes may cause permanent damage. Hyaluronidase + systemic treatment should be performed, neuro-ophthalmology STAT consultation is required in case of suspicion of ophthalmic artery embolization.

Related Terms

• Hyaluronidase (Drug) — Enzyme Sheet (Batch 6) — Molecular biochemistry, sources, formulations, side effects of hyaluronidase
• Tyndall Effect — Optical complication after superficial injection of HA filler
• Filler Nodule — Granuloma and biofilm formation
• Vascular Occlusion — HA embolization emergency
• Fill Migration — Displacement of HA filler
• Hyaluronic Acid (HA) — Filler
• Filler — Aesthetic injection general
• Lip Filler — Lip enhancement

Frequently Asked Questions

1. Is hyaluronidase injection painful?

   "Hyaluronidase injection may be a little more painful than standard HA filler injection — because the complication area (swelling, nodule, vascular congestion) is already sensitive. Local anesthesia (topical EMLA or intradermal lidocaine) can keep the pain minimal. Needle-on-needle injection pain is mild-moderate; cold anesthesia (cryotherapy) is not preferred, the injection rate is slow and can be controlled with technical accuracy. In vascular occlusion emergency, anesthesia becomes secondary (time is critical) — topical Benzocaine spray provides only mild anesthesia but accelerates the procedure."

2. When will I see results after hyaluronidase injection?

   "Timing of results depends on which complication you are treating. Tyndall effect: Mostly resolved in 24-72 hours. Nodule: 1-2 weeks (granuloma slower, 4+ weeks). Overfilling: Partial recovery in 1-2 weeks, full in 3-4 weeks. In vascular occlusion emergency: Skin heals if reperfusion is achieved in 24-48 hours; advanced ischemia carries risk of necrosis over 72 hours."

3. Is one session of hyaluronidase sufficient or is repeat injection required?

   "For most mild-moderate complications (Tyndall, nodule, asymmetry), one session is sufficient. If the remaining residue is minimal, re-injection can be done after 2-4 weeks. Large overfill or vascular occlusion: the first session is performed with flood technique, if repeat is necessary after 24-48 hours of observation (residual volume, pain, color abnormalities), the second session can be done 48 hours later. Two sessions at the same time are NEVER performed on the same day (risk of hemostasis deterioration, joint effusion)."

4. I am allergic to hyaluronidase — can it be done?

   "If hyaluronidase has previously had anaphylaxis/severe reaction, recombinant (Hylenex) should definitely be preferred — <0.01% risk of anaphylaxis vs. bovine 0.1-1%. If Hylenex is not easily accessible and the product is in an emergency situation, intradermal testing (3 U × 20 minutes observation) can be done — if negative, proceed (but IM epinephrine should be ready). In case of suspicion of emergency vascular occlusion, even if allergic risk/benefit opens — life vs. allergic reaction, hyaluronidase is administered and epinephrine is kept on standby when signs of allergic reaction (pruritus, urticaria, dyspnea, angioedema) appear, epinephrine 0.3-0.5 mg IM is administered and STAT hospital reference.”

5. How soon can I have a new filler after hyaluronidase?

   "After applying hyaluronidase, a minimum of 2 weeks should be waited. In the first 48 hours, there is a peak of edema and inflammation; new filler injection increases irritation. After 2 weeks, the swelling has subsided and the side effects of hyaluronidase have been minimized. Thus, the new injection technique can be applied safely to the right area, at the right depth. In case of vascular occlusion emergency, refilling is considered after a minimum of 1 month (after revascularization is confirmed and skin integrity is restored)."

6. Will hyaluronidase also disrupt my natural HA?

   "No — hyaluronidase is selective. Just as it breaks down HA filler, it can theoretically break down natural skin, tendon, ligament, subcutaneous tissue HA, but practical dialysis is very rare. Reason: (1) the body HA pool is very large compared to the injected dose; (2) hyaluronidase becomes inactive in a short time (hours); (3) the body rapidly replenishes the natural HA (continuing with fibroblast collagen synthesis). "Dermatologists normally do not see any problems with hyperpigmentation, scarring, or skin elasticity after hyaluronidase. Very high doses of overcorrection or incorrect deep injection may carry theoretical risks, but experienced physicians keep this to a minimum with dose-controlled injection."

7. Is hyaluronidase injection expensive? Does insurance cover it?

   This page does not provide a fixed online price quote. The final fee depends on physician assessment, treatment area, product amount or brand, combination planning and medical suitability.

8. Can hyaluronidase be administered during pregnancy?

   "FDA category C (limited data). Filler complications during pregnancy are rare — as pregnant women often postpone new fillers. If there are serious complications (e.g. risk of vascular occlusion), the risk/benefit is discussed and consultation with the obstetrician is made. Hyaluronidase systemic absorption is minimal (natural enzyme breaks down), but hematological file (oxygen, inflammation) may interfere with pregnancy. Precaution: postpone until pregnancy is completed or "It is consulted and applied ultra-carefully."

9. Does retrobulbar hyaluronidase for ophthalmic artery occlusion really work?

   "Retrobulbar hyaluronidase is a controversial treatment in the emergency of ophthalmic artery embolization (risk of blindness). Theoretically: high dose hyaluronidase (150-300 U) can be injected directly into the retrobulbar area, disintegrating the HA filler in the zone surrounding the embolized vessel and reperfusion can be achieved. In practice: (1) Retrobulbar injection carries technical difficulty and risk of eye damage (retinal artery, optic nerve). (2) Efficacy is still uncertain." (limited case report) (3) Standard ASDS 2017 protocol does not mention retrobulbar hyaluronidase — STAT ophthalmic consultation, CBS/MRA angiography, hyperbaric oxygen, anticoagulation are recommended before. Retrobulbar hyaluronidase is considered together with neuroophthalmologist and ultima ratio.”

10. Can I make hyaluronidase myself at home?

    "Absolutely NO. Hyaluronidase injection is a medical procedure and should be performed in a clinical setting by an experienced aesthetic physician, dermatologist, plastic surgeon. Reasons: (1) Enzyme preparation, dose calculation, product selection require medical knowledge. (2) Risk of vascular/neural damage if the injection technique is performed incorrectly (wrong depth, location, angle). (3) Serious reaction such as anaphylaxis is rare but may occur — epinephrine, antihistamine, oxygen, hospital reference is readily available in the clinical setting. (4) Rapid multi-modal treatment in vascular occlusion emergency is critical, DIY hyaluronidase injection should be prohibited in the home setting; risk of medical malpractice and criminal law in case of violation.”

Resources

1. Landau M. "Hyaluronidase Caveats and Complications: A Systematic Review."
   Authors: Landau M
   Publisher: PubMed / Dermatologic Surgery
   Year: 2015
   URL: https://pubmed.ncbi.nlm.nih.gov/25629382/
2. DeLorenzi C. “Complications of Injected Fillers, Part 2: Vascular Occlusion.”
   Authors: DeLorenzi C
   Publisher: PubMed / Facial Plastic Surgery
   Year: 2017
   URL: https://pubmed.ncbi.nlm.nih.gov/28283948/
3. Cavallini M, et al. "Immunogenicity of Hyaluronidase in Cosmetic Dermatology."
   Authors: Cavallini M, Schipani G, Manetti M
   Publisher: PubMed / Journal of Cosmetic Dermatology
   Year: 2013
   URL: https://pubmed.ncbi.nlm.nih.gov/24305449/
4. André P. “Hyaluronidase: Indications and Protocols for HA Filler Reversal.”
   Authors: André P
   Publisher: ASDS / Dermatologic Surgery
   Year: 2008
   URL: https://pubmed.ncbi.nlm.nih.gov/18691080/
5. ASDS (American Society for Dermatologic Surgery). "Emergency Management of Filler Complications." Consensus Guidelines 2017.
   Publisher: ASDS Clinical Guidelines
   Year: 2017
   URL: https://www.asds.net/clinical-resources
6. FDA Hylenex Recombinant (Hyaluronidase Injectable) — Full Prescribing Information and Safety Data.
   Publisher: U.S. Food and Drug Administration
   Year: 2005 (approved), updated 2023
   URL: https://www.accessdata.fda.gov/drugsatfda_docs/label/
7. Kim JE, et al. “Hyaluronidase Allergy Testing and Management in Aesthetic Dermatology.”
   Authors: Kim JE, Park CS, Suh HS
   Publisher: PubMed / Contact Dermatitis
   Year: 2011
   URL: https://pubmed.ncbi.nlm.nih.gov/21644941/

Last update: April 23, 2026 · Medical editor: Dr. Hamza Gemici